المساهمون: Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Evgeny Kopyltsov, María J Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung-Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R Merchan, Eric Winquist, Pablo Maroto, Jeffrey C Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E Dutcus, Alan D Smith, Lea Dutta, Kalgi Mody, Rodolfo F Perini, Dongyuan Xing, Toni K Choueiri, Rha, Sun Young

مصطلحات موضوعية: Adult, Aged, 80 and over, Antibodies, Monoclonal, Humanized / administration & dosage, Humanized / adverse effects, Antineoplastic Agents / adverse effects, Antineoplastic Agents / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Carcinoma, Renal Cell / drug therapy, Renal Cell / mortality, Everolimus / administration & dosage, Everolimus / adverse effects, Female, Humans, Kidney Neoplasms / drug therapy, Kidney Neoplasms / mortality, Male, Middle Aged, Phenylurea Compounds / administration & dosage, Phenylurea Compounds / adverse effects, Programmed Cell Death 1 Receptor / antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors / therapeutic use, Quinolines / administration & dosage, Quinolines / adverse effects, Sunitinib / adverse effects

العلاقة: NEW ENGLAND JOURNAL OF MEDICINE; J02371; OAK-2021-06182; https://ir.ymlib.yonsei.ac.kr/handle/22282913/185460Test; T202104165; NEW ENGLAND JOURNAL OF MEDICINE, Vol.384(14) : 1289-1300, 2021-04

الإتاحة: https://doi.org/10.1056/NEJMoa2035716Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/185460Test

المساهمون: College of Medicine, Dept. of Internal Medicine, Kyong Joo Lee, Jae Hee Cho, Sang Hyub Lee, Si Young Song, Kwang Hyuk Lee, Seok Jeong, Ji Kon Ryu, Sang Myung Woo, Seungmin Bang, Jong Kyun Lee, Tae Hoon Lee, Woo Hyun Paik, Yong Tae Kim, Woo Jin Lee, Bang, Seung Min, Song, Si Young

مصطلحات موضوعية: Adult, Aged, 80 and over, Anemia/chemically induced, Anemia/epidemiology, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Disease-Free Survival, Everolimus/adverse effects, Everolimus/therapeutic use, Exanthema/chemically induced, Exanthema/epidemiology, Female, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Pancreatic Neoplasms/drug therapy, Pancreatic Neoplasms/pathology, Prognosis, Republic of Korea, Retrospective Studies, Stomatitis/chemically induced, Stomatitis/epidemiology, Treatment Outcome, Young Adult, Everolimus, Pancreatic neuroendocrine tumor

العلاقة: CANCER CHEMOTHERAPY AND PHARMACOLOGY; J00437; OAK-2017-05183; https://ir.ymlib.yonsei.ac.kr/handle/22282913/160894Test; https://link.springer.com/article/10.1007%2Fs00280-017-3421-7Test; T201703544; CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.80(4) : 799-805, 2017

الإتاحة: https://doi.org/10.1007/s00280-017-3421-7Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/160894Test

المساهمون: College of Medicine, Dept. of Internal Medicine, S. J. Kim, D.-Y. Shin, J. S. Kim, D. H. Yoon, W. S. Lee, H. Lee, Y. R. Do, H. J. Kang, H. S. Eom, Y. H. Ko, S. H. Lee, H. Y. Yoo, M. Hong, C. Suh, W. S. Kim, Kim, Jin Seok

مصطلحات موضوعية: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cyclophosphamide/administration & dosage, Cyclophosphamide/adverse effects, Disease-Free Survival, Doxorubicin/administration & dosage, Doxorubicin/adverse effects, Drug Administration Schedule, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Lymphoma, T-Cell, Peripheral/drug therapy, Peripheral/pathology, Male, Middle Aged, Neoplasm Staging, PTEN Phosphohydrolase/biosynthesis, PTEN Phosphohydrolase/genetics, Prednisone/administration & dosage, Prednisone/adverse effects, TOR Serine-Threonine Kinases/antagonists & inhibitors, TOR Serine-Threonine Kinases/genetics, Treatment Outcome, Vincristine/administration & dosage, Vincristine/adverse effects

العلاقة: ANNALS OF ONCOLOGY; J00171; OAK-2016-07707; https://ir.ymlib.yonsei.ac.kr/handle/22282913/152779Test; T201605305; ANNALS OF ONCOLOGY, Vol.27(4) : 712-718, 2016

الإتاحة: https://doi.org/10.1093/annonc/mdv624Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152779Test

المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators

المساهمون: Gennigens, Christine

المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)

مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406

الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test